Why the study?
It has been difficult to experimentally reproduce the synergistic effects of ketoconazole on terfenadine-induced torsade de pointes.
Does ketoconazole pretreatment increase terfenadine-induced torsade de pointes in chronic atrioventricular block cynomolgus monkeys?
Does ketoconazole pretreatment increase terfenadine-induced torsade de pointes in chronic atrioventricular block cynomolgus monkeys?
The chronic atrioventricular block cynomolgus monkey is a viable in vivo model for evaluating drug interaction-associated torsade de pointes.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to potential TdP risk with terfenadine plus CYP3A inhibitors; leaves open validation of this primate model for drug-interaction proarrhythmia screening.
It has been difficult to experimentally reproduce synergistic effects of ketoconazole on terfenadine-induced torsade de pointes. We assessed proarrhythmic effects of terfenadine (30 mg/kg, p.o.) with/without ketoconazole (100 mg/kg, p.o.) pretreatment using the chronic atrioventricular block cynomolgus monkeys with repeated-measured design (n = 4). Terfenadine with ketoconazole pretreatment repeatedly induced non-sustained torsade de pointes in each animal, although terfenadine alone did not induce it at all. Thus, the chronic atrioventricular block cynomolgus monkeys can be used for studying drug interaction-associated torsade de pointes, providing a non-clinical strategy to circumvent untoward drug interactions in patients specially under polypharmacy.
No takes yet. Share an insight, caveat, or question.
Goto et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: